Our platform centers on patented epitope-engineering technology, creating mini-proteins that mimic challenging conformational epitopes, including subdominant ones. Epitopes are specific regions on a target protein where antibodies bind. Traditional drug discovery tends to prioritize immunodominant epitopes, often missing the more effective subdominant epitopes. Epitope steering addresses this gap by uncovering the best therapeutic antibodies from subdominant epitopes.

​

SwiftPharma's ODIN.AI antibody discovery platform combines artificial intelligence, big data, and machine learning to generate a novel artificial intelligence (AI)-powered computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates with high specificity and affinity at unprecedented speed.